Showing results (151-160 of 203) with videos related to
Sort By:
Pageof 21
Lancet (London, England)|August 28, 2009
Achieving the health Millennium Development Goals for South Africa: challenges and prioritiesMickey Chopra, Joy E Lawn, David Sanders, et al.The Journal of Infectious Diseases|January 18, 2014
Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trialXierong Wei, Gillian Hunt, Salim S Abdool Karim, et al.Journal of the International AIDS Society|February 21, 2025
Acceptability of an annual tenofovir alafenamide implant for HIV prevention in South African women: findings from the CAPRISA 018 Phase I clinical trialTanuja N Gengiah, Craig J Heck, Lara Lewis, et al.Journal of Clinical Microbiology|December 28, 2013
Limited HIV-1 superinfection in seroconverters from the CAPRISA 004 Microbicide TrialAndrew D Redd, Caroline E Mullis, Sarah K Wendel, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|February 11, 2017
Genital-Systemic Chemokine Gradients and the Risk of HIV Acquisition in WomenLenine J P Liebenberg, Lindi Masson, Kelly B Arnold, et al.The Lancet. HIV|July 20, 2018
Community-based HIV prevalence in KwaZulu-Natal, South Africa: results of a cross-sectional household surveyAyesha B M Kharsany, Cherie Cawood, David Khanyile, et al.Trials|December 21, 2014
Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trialLeila E Mansoor, Quarraisha Abdool Karim, Kathryn T Mngadi, et al.Cell Host & Microbe|October 2, 2018
HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization BreadthDaniel J Sheward, Jinny Marais, Valerie Bekker, et al.Nature Communications|September 1, 2025
Hyaluronidase-enhanced subcutaneous delivery of bNAbs: a phase 1 randomized controlled clinical trial in HIV-uninfected womenSharana Mahomed, Farzana Osman, Martin Beliveau, et al.Plos One|September 10, 2013
No evidence for selection of HIV-1 with enhanced gag-protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trialDenis R Chopera, Jaclyn K Mann, Philip Mwimanzi, et al.Pageof 21